Abstract 955P
Background
The field of systemic therapy in hepatocellular carcinoma (HCC) has significantly evolved over the last years, and IO-based combinations therapies are the current standard of care. Nivolumab is a recombinant human IgG4 mAb targeting PD-1 with clinically meaningful activity in about 15-20% of HCC patients. Combinations of anti- angiogenic multikinase inhibitors, including lenvatinib, and PD-1/PD-L1 inhibitors have demonstrated remarkable antitumor activity with manageable toxicity in several tumor types, including HCC. The IMMUNIB trial aimed to evaluate the efficacy of nivolumab in combination with lenvatinib as first line treatment in patients with advanced HCC.
Methods
This investigator-initiated single-armed phase II trial (NCT03841201) recruited 50 patients (pts) at 8 sites in Germany between 06/2019 and 05/2021. Primary efficacy endpoint was objective response rate (ORR) according to investigator assessed RECIST 1.1. Secondary endpoints included time to progression (TTP), progression free survival (PFS), overall survival (OS) and safety.
Results
Out of 50 enrolled pts (24 BCLC B, 18 BCLC C, 7 not evaluable) 49 received at least one dose of the combination treatment. The ORR by RECIST 1.1 was 32% (CR 6%, PR 26%, SD 42%, PD 12%). Median PFS was 9.0 mo. Median TTP was 9.89 mo (0.7 at 6 mo, 0.43 at 12 mo, 0.31 at 18 mo) and median OS was 25.36 mo (24 events). Of note, at EOS 26 pats were still alive, of whom 13 pats were without progression. 47 (96%) pts experienced at least one TRAE, of which 29 pts (59%) encountered at least one TRAE ≥ grade 3. 16 (32.7%) pts had at least one SAE related to the study medication, whereof 14 pts (29%) experienced at least one treatment related SAE ≥ grade 3.
Conclusions
No new safety signals were observed for the combination of nivolumab and lenvatinib. Although the study failed to reach its prespecified ORR of at least 43%, the high activity in all efficacy endpoints with a mOS of more than 25 mo supports the further investigation of the combination in HCC.
Clinical trial identification
EudraCT 2018-001480-23, NCT03841201.
Editorial acknowledgement
Legal entity responsible for the study
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest.
Funding
EEISAI GmbH Contact person: Dominik Peters, Edmund-Rumpler-Straße Str. 3, D-60549 Frankfurt, Germany, Email: Dominik_Peters@eisai.net AND Bristol Myers Squibb GmbH & Co. KGaA Contact person: Sandra Gruenbaum, Arnulfstraße 29, D-80636 München, Germany, Email: sandra.gruenbaum@bms.com
Disclosure
A. Vogel: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Böhringer Mannheim, EISAI, INCYTE, Ipsen, Janssen, MSD, PierreFabre, Roche, Servier, Sirtex, Tyra, Tahio; Financial Interests, Personal, Invited Speaker: BMS, Eisai, Incyte, Ipsen, Lilly, MSD, Roche; Financial Interests, Personal, Steering Committee Member: Roche, MSD, BeiGene, Jiangsu Hengrui Medicines.. A. Saborowski: Financial Interests, Financially compensated role: Servier, Roche, BMS. G.M. Siegler: Financial Interests, Personal, Advisory Board: BMS, Novartis, Roche, MSD, Janssen; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Institutional, Local PI: BMS, MSD, AstraZeneca; Non-Financial Interests, Principal Investigator: BMS, MSD, AIO GmbH, IKFZ, AstraZeneca, GLA; Non-Financial Interests, Member: AIO GmbH, DGHO, EORTC, DKG. M. Schultheiss: Financial Interests, Writing Engagement: Falk Foundation e.V:; Financial Interests, Advisory Board: Bayer Healthcare, Bristol Myers Squibb. S. Al-Batran: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, MacroGenics, Immutep, MSD Sharp & Dohme; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Lilly, AIO Studien gGmbH, MCI Deutschland GmbH; Financial Interests, Personal, Other, CEO/founder: Institute of Clinical Cancer Research IKF at Northwest Hospital; Financial Interests, Institutional, Research Grant: Sanofi, Roche, Celgene, Vifor, Medac, Hospira, Lilly, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, MSD Sharp & Dohme, AstraZeneca, German Cancer Aid (Krebshilfe), German Research Foundation, Federal Ministry of Education and Research. E. De Toni: Financial Interests, Other: AstraZeneca, BMS, Bayer, Eisai, Pfizer, Ipsen, Eli Lilly & Co, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18